Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Pesaran

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|February 25, 2020
The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing CohortChunling Hu, Eric C Polley, Siddhartha Yadav, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 22, 2018
Correction: DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genesMarcy E Richardson, Hansook Chong, Wenbo Mu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 29, 2018
DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genesMarcy E Richardson, Hansook Chong, Wenbo Mu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 20, 2019
Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohortHongyan Li, Holly LaDuca, Tina Pesaran, et al.
Frontiers in Oncology|November 10, 2018
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein InteractionLaura Caleca, Irene Catucci, Gisella Figlioli, et al.
NPJ Genomic Medicine|June 6, 2022
An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significanceEdwin S Iversen, Gary Lipton, Steven N Hart, et al.
JCO Precision Oncology|September 10, 2019
Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility GenesChunling Hu, Holly LaDuca, Hermela Shimelis, et al.
Human Molecular Genetics|January 25, 2024
Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelinesCristina Fortuno, Kyriaki Michailidou, Michael Parsons, et al.
Human Mutation|October 13, 2018
Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert PanelJessica L Mester, Rajarshi Ghosh, Tina Pesaran, et al.
American Journal of Human Genetics|February 20, 2021
Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significanceMarcy E Richardson, Chunling Hu, Kun Y Lee, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|February 25, 2020
The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing CohortChunling Hu, Eric C Polley, Siddhartha Yadav, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 22, 2018
Correction: DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genesMarcy E Richardson, Hansook Chong, Wenbo Mu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 29, 2018
DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genesMarcy E Richardson, Hansook Chong, Wenbo Mu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 20, 2019
Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohortHongyan Li, Holly LaDuca, Tina Pesaran, et al.
Frontiers in Oncology|November 10, 2018
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein InteractionLaura Caleca, Irene Catucci, Gisella Figlioli, et al.
NPJ Genomic Medicine|June 6, 2022
An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significanceEdwin S Iversen, Gary Lipton, Steven N Hart, et al.
JCO Precision Oncology|September 10, 2019
Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility GenesChunling Hu, Holly LaDuca, Hermela Shimelis, et al.
Human Molecular Genetics|January 25, 2024
Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelinesCristina Fortuno, Kyriaki Michailidou, Michael Parsons, et al.
Human Mutation|October 13, 2018
Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert PanelJessica L Mester, Rajarshi Ghosh, Tina Pesaran, et al.
American Journal of Human Genetics|February 20, 2021
Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significanceMarcy E Richardson, Chunling Hu, Kun Y Lee, et al.
Pageof 9